These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1429 related items for PubMed ID: 21107514

  • 1. [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
    Silber S.
    Herz; 2010 Dec; 35(8):558-64. PubMed ID: 21107514
    [Abstract] [Full Text] [Related]

  • 2. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U, Mochmann HC, Mark B, Arntz HR, Thiele H, Diller F, Montalescot G, Zahn R.
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [Abstract] [Full Text] [Related]

  • 3. [The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Three case reports].
    Silber S, Richartz BM, Brilmayer M, European Society of Cardiology (ESC).
    Herz; 2006 Dec; 31(9):836-46, 848. PubMed ID: 17180646
    [Abstract] [Full Text] [Related]

  • 4. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Tölg R, Anette Fiedler K, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A, Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators.
    Eur Heart J; 2014 Sep 07; 35(34):2285-94. PubMed ID: 24816809
    [Abstract] [Full Text] [Related]

  • 5. Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).
    Morrison DA, Berman M, El-Amin O, McLaughlin RT, Bates ER.
    Minerva Cardioangiol; 2007 Oct 07; 55(5):593-623. PubMed ID: 17912165
    [Abstract] [Full Text] [Related]

  • 6. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
    Schulz S, Richardt G, Laugwitz KL, Mehran R, Gershlick AH, Morath T, Mayer K, Neudecker J, Tölg R, Ibrahim T, Hauschke D, Braun D, Schunkert H, Kastrati A, Mehilli J, Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators.
    Clin Cardiol; 2014 May 07; 37(5):270-6. PubMed ID: 24633823
    [Abstract] [Full Text] [Related]

  • 7. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P, Grieco N, Ince H, Danchin N, Goedicke J, Ramos Y, Schmitt J, Goldstein P, MULTIPRAC study investigators.
    Eur Heart J Acute Cardiovasc Care; 2015 Jun 07; 4(3):220-9. PubMed ID: 25182465
    [Abstract] [Full Text] [Related]

  • 8. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA, Braunwald E, Antman EM, Murphy SA, Montalescot G, Wiviott SD.
    JACC Cardiovasc Interv; 2014 Jun 07; 7(6):604-12. PubMed ID: 24947719
    [Abstract] [Full Text] [Related]

  • 9. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators.
    Lancet; 2009 Feb 28; 373(9665):723-31. PubMed ID: 19249633
    [Abstract] [Full Text] [Related]

  • 10. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
    Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, Brown E, Miller DL, LeNarz L, Vicaut E, ACCOAST Investigators.
    J Am Coll Cardiol; 2014 Dec 23; 64(24):2563-2571. PubMed ID: 25524333
    [Abstract] [Full Text] [Related]

  • 11. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G, Siller-Matula JM, Francesconi M, Dechant C, Grohs K, Podczeck-Schweighofer A.
    BMJ Open; 2014 Oct 31; 4(10):e005781. PubMed ID: 25361837
    [Abstract] [Full Text] [Related]

  • 12. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD.
    J Am Coll Cardiol; 2014 Jan 28; 63(3):225-32. PubMed ID: 24140678
    [Abstract] [Full Text] [Related]

  • 13. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G, Savonitto S, van't Hof AW, Suryapranata H.
    Drugs; 2015 Jul 28; 75(11):1229-53. PubMed ID: 26177890
    [Abstract] [Full Text] [Related]

  • 14. Review of prasugrel for the secondary prevention of atherothrombosis.
    Spinler SA, Rees C.
    J Manag Care Pharm; 2009 Jun 28; 15(5):383-95. PubMed ID: 19496635
    [Abstract] [Full Text] [Related]

  • 15. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
    Beigel R, Fefer P, Rosenberg N, Novikov I, Elian D, Fink N, Segev A, Guetta V, Hod H, Matetzky S.
    Am J Cardiol; 2013 Nov 15; 112(10):1551-6. PubMed ID: 23972349
    [Abstract] [Full Text] [Related]

  • 16. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology.
    Bassand JP, Danchin N, Filippatos G, Gitt A, Hamm C, Silber S, Tubaro M, Weidinger F.
    Eur Heart J; 2005 Dec 15; 26(24):2733-41. PubMed ID: 16311237
    [Abstract] [Full Text] [Related]

  • 17. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
    Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Rabbani LE, Parise H, Stone GW, HORIZONS-AMI Trial Investigators.
    J Am Coll Cardiol; 2009 Oct 06; 54(15):1438-46. PubMed ID: 19796737
    [Abstract] [Full Text] [Related]

  • 18. Critical review of prasugrel for formulary decision makers.
    Schafer JA, Kjesbo NK, Gleason PP.
    J Manag Care Pharm; 2009 May 06; 15(4):335-43. PubMed ID: 19422273
    [Abstract] [Full Text] [Related]

  • 19. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J, Bellemain A, Ecollan P, Montalescot G, Collet JP.
    Presse Med; 2011 Jun 06; 40(6):615-24. PubMed ID: 21511430
    [Abstract] [Full Text] [Related]

  • 20. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
    Nührenberg TG, Trenk D, Leggewie S, Ristau I, Amann M, Stratz C, Hochholzer W, Valina CM, Neumann FJ.
    Platelets; 2013 Jun 06; 24(7):549-53. PubMed ID: 23216528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.